



Perma-Fix Medical Provides Business Update

Schedules Investor Webcast for November 19th at 2:00 PM Central European Time

Wroclaw and Atlanta – November 19, 2015 – Perma-Fix Medical S.A. (WAR: PFM), a subsidiary of Perma-Fix Environmental Services, Inc., a NASDAQ listed company, today provided a general business update. The Company also announced it will host a business update call at 2:00 PM Central European time (8:00 a.m. Eastern time) on Thursday, November 19, 2015, via webcast on the company’s website: www.medical-isotope.com.

Steve Belcher, Chief Executive Officer of Perma-Fix Medical S.A stated, “We are pleased to report a number of important developments at Perma-Fix Medical that will play an important role in accelerating our progress toward commercial launch of our innovative process to produce Technetium-99 (Tc-99m). In early September, we completed another successful scale-up of our prototype generator for commercial production of Tc-99m. The tests confirmed that our proprietary resin could withstand higher levels of radiation, up to 6 curies. Based on these results, we remain convinced that our process has the potential to reshape the multi-billion dollar global supply chain of Tech-99 in the United States and around the world. Moreover, we believe we are now very close to overcoming nearly all the technical hurdles related to our resin. We are now in a position to meet the requirements of customers, not only in emerging markets, but also in North American and European markets.”

“Following the earlier success at the 2 and 4 curie level, we have witnessed growing interest from within the industry—further validating the significance of our process. We have received positive feedback from industry leaders during the US Department of Energy Molly-99 Topical meeting in Boston in September and recently at the National Academies of Sciences, Engineering and Medicine - Nuclear and Radiation Studies Board committee meeting in Washington, DC.”

“Based on our latest success at the 6 curie level, we are conducting additional tests at higher curie levels and will provide more updates on this front in the very near future. In the meantime, we are in active discussions with a number of key industry players involved in other areas of the supply chain for Tc-99m. We expect to move ahead with submitting both FDA and CE applications in the near future.”

Nearly all of the world’s supply of Tc-99m comes from the thermal fission of highly enriched uranium (HEU) targets in a small number of highly specialized reactors. The current process is costly and has proven an unreliable source of radioactive material leading to severe worldwide shortages. The scheduled closure of the NRU reactor in 2016 and the OSIRIS reactor in France in 2018 are expected to have a further impact on the manufacturing and supply of these isotopes. The current process also raises serious proliferation concerns related to the threat associated with international production, transportation and/or use of HEU in the production of medical isotopes.

Perma-Fix's technology has the potential to overcome these issues by using neutron capture to activate natural Molybdenum, a common metal, to produce Mo-99, which decays into Tc-99m. Unlike conventional processes, the Perma-Fix Medical process can be produced locally using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. The new process encompasses the full production cycle, from reactor to final medical supply, and should be easily deployable around the world.

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical is a subsidiary of Perma-Fix Environmental Services Inc., a NASDAQ listed company. It was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors.

Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszewska or David K. Waldman
Crescendo Communications Europe Sp. z.o.o
Tel: (+48 71) 79 11 551
Email : pfm@crescendo-ir.com